Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
October 11, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of...
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry Conference
September 29, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and...
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
September 27, 2022 07:32 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on...
Cognition Therapeutics Announces Participation in September Investment Conferences
September 06, 2022 07:32 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery...
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022 07:00 ET
|
Cognition Therapeutics, Inc.
Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer’s DiseasePositive Preliminary Data for Dry AMD Program Presented at ARVO 2022Proteomics Data from SPARC read out at AAIC ...
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes
August 04, 2022 16:02 ET
|
Cognition Therapeutics, Inc.
NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Mary Hamby, Ph.D., vice president of research, presented results at the at Alzheimer’s...
Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
August 03, 2022 16:05 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease
July 19, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
- Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be in attendance at the 2022...
Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
June 23, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE...
Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference
June 08, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th....